252 results
Page 2 of 13
DEFM14A
6t5u29
13 Apr 23
Proxy related to merger
4:52pm
424B5
qiw9k
23 Sep 22
Prospectus supplement for primary offering
5:05pm
8-K
uox0x 2kasd
21 Sep 22
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
4:10pm
8-K
EX-99.1
pkze zyp4o9ln
21 Sep 22
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
4:10pm
DEFA14A
u0k7b71
18 Aug 22
Additional proxy soliciting materials
3:07pm
8-K
EX-99.1
r93 gh6k8
10 Aug 22
Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
pj51u6zlps4j 9pucs
1 Aug 22
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
6:10am
8-K
f3xloljuotrmvh
1 Aug 22
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
6:10am
DEFA14A
EX-10.1
wf2ljlvcu2ae857ixrj
6 Jul 22
Additional proxy soliciting materials
6:04am
8-K
EX-10.1
u8m3g66r
6 Jul 22
Entry into a Material Definitive Agreement
6:04am
8-K
EX-10.1
ux04hddccc2syax 26
24 Jun 22
Entry into a Material Definitive Agreement
4:35pm
8-K
EX-3.1
ktgmz7sa in
17 Jun 22
Material Modifications to Rights of Security Holders
4:25pm
8-K
EX-99.1
3y20 xw0zpb1
18 May 22
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
7:53pm
8-K
EX-10.2
6vhf001dup7cad
18 May 22
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
7:53pm
8-K
EX-10.1
zio s747jo
18 May 22
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
7:53pm